Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopropylamine SCHEMBL2350740 | 0.88 | CYP2D6 (0.53) | GBA1CYP2D6MAPK1ALDH1A1CA2 | |
| SCHEMBL6517716 | 0.88 | CA2 (0.47) | GBA1CYP2D6MAPK1ALDH1A1CA2 | |
| SCHEMBL29024359 | 0.87 | ALDH1A1 (0.46) | GBA1CYP2D6MAPK1ALDH1A1CA2 | |
| Butanol SCHEMBL7695797 | 0.87 | ALDH1A1 (0.46) | GBA1CYP2D6MAPK1ALDH1A1CA2 | |
| Butanol SCHEMBL7695800 | 0.87 | ALDH1A1 (0.46) | GBA1CYP2D6MAPK1ALDH1A1CA2 | |
| SCHEMBL1274859 | 0.86 | CYP2D6 (0.51) | GBA1CYP2D6MAPK1ALDH1A1CA2 | |
| SCHEMBL6959918 | 0.85 | ALDH1A1 (0.45) | GBA1CYP2D6MAPK1ALDH1A1CA2 | |
| SCHEMBL8178505 | 0.85 | ALDH1A1 (0.47) | CYP2D6MAPK1ALDH1A1CA2CA1 | |
| SCHEMBL29024318 | 0.85 | ALDH1A1 (0.47) | CYP2D6MAPK1ALDH1A1CA2CA1 | |
| Isopropylamine SCHEMBL3156276 | 0.85 | CYP2D6 (0.50) | GBA1CYP2D6MAPK1ALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2429535-A2 | COMPOSITIONS AND METHODS FOR TREATING BURNS | Mindcake, LLC (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010123759-A2 | COMPOSITIONS AND METHODS FOR TREATING BURNS | HICKS TERRY LEE (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100266709-A1 | Compositions and Methods for Treating Burns | MINDCAKE LLC | 2010-10-21 | — | — | US | disclosed |
| US-7604797-B2 | Administering to a burn an anticytokine or antiinflammatory agent and a pharmaceutically excipient; administering to a mammal having a burn injury:sodium monofluorophosphate and a dihydrofolate reductase inhibitor of aminopterin, methotrexate, pyramethamine, trimethoprim or derivatives | BIOMECHANISMS INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080279820-A1 | Compositions and Methods for Treating Burns | MINDCAKE LLC | 2008-11-13 | — | — | US | disclosed |
| EP-1667648-A2 | COMPOSITIONS AND METHODS FOR TREATING BURNS | Kohi Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050281820-A1 | Compositions and methods for treating burns | MINDCAKE LLC | 2005-12-22 | — | — | US | disclosed |
| WO-2005032470-A2 | COMPOSITIONS AND METHODS FOR TREATING BURNS | KOHI CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279820-A1 | Compositions and Methods for Treating Burns | TNF, CD68, MMP8 | GBA1 731/4885CYP2D6 3185/4885MAPK1 2901/4885 |
| US-20050281820-A1 | Compositions and methods for treating burns | TNF, CD68, MMP8 | GBA1 754/4885CYP2D6 3229/4885MAPK1 3010/4885 |
| US-20100266709-A1 | Compositions and Methods for Treating Burns | TNF, CD68, MMP8 | GBA1 755/4885CYP2D6 3316/4885MAPK1 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.